by SHAFIQQUL ALIFF/ Pic courtesy of MGRC
UCREST Bhd and Malaysian Genomics Resources Centre Bhd (MGRC) signed a collaborative agreement to integrate genomic testing services into the digital health platform, iMedic™️, elevating healthcare services to the next level.
UCrest CEO Eg Kah Yee said a virtual genome service centre will be developed under this agreement on iMedic™️ enabling the genomic testing services of MGRC to be made available to the hospitals and clinics (B2B), widening its market access globally.
Eg said the genomic testing services additionally will also be made available to patients directly (B2C).
“Patients’ genomic data from their test results will be integrated into electronic medical records making it accessible by doctors and patients in the process of consultation and management, resulting in improved accuracy in diagnosis and treatment.
“This partnership with MGRC allows them to enhance their vision of integrating preventive and precision medicine into iMedic™️ where genome data will empower the patients to better prevent and manage chronic diseases with the online consultation of doctors,” he said in a virtual press conference today.
According to Eg, the global genomics market size was valued at US$20.1 billion (RM89.43 billion) in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.35% from 2021 to 2028.
“The Asia Pacific genome sequencing market will grow by 15.6% annually over 2022-2030 due to growing government funding initiatives in genomics projects related to cancer treatment and the utilisation of genomics in personalised medicine targeting chronic disease prevention and management,” he added.
UCrest is the leading technology provider of digital health platforms with offices in Malaysia, Singapore, China and Taiwan providing access to thousands of doctors, including many from the leading hospitals in the US and China, to provide online consultation and management of patients anywhere in the globe.
Meanwhile, MGRC CEO Sasha Nordin said the collaboration plays an important role in providing physicians with easy access to the latest in genetic screening, in support of enhancing their medical practice and improving patient outcomes.
“We are looking forward to working with UCrest as its iMedic™️ platform will provide us an opportunity to reach out to markets beyond Malaysia.
“The platform will also enable us to strengthen our B2B and B2C channels which is the critical part and is very consumer-centric where we realise that we cannot afford to maintain the B2B channel,” he said.
MGRC is a leading genomics and biopharmaceutical company in Asean for genome sequencing, bioinformatics analysis and genetic screening, and various types of immunotherapies including CAR T-Cell therapy for the treatment of certain cancers.